Gilead Sciences (GILD) Other Non-Current Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Other Non-Current Liabilities for 18 consecutive years, with $1.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities rose 15.5% year-over-year to $1.5 billion; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 15.5% YoY), and the FY2025 full-year result was $1.2 billion, down 10.04% from the prior year.
• Other Non-Current Liabilities advanced to $1.5 billion in Q2 2026 per GILD's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.8 billion in Q1 2022 and bottomed at $1.2 billion in Q4 2025.
• Historically, Other Non-Current Liabilities has averaged $2.3 billion across 5 years, with a median of $1.7 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities tumbled 47.93% in 2023, then grew 15.5% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $3.9 billion in 2022, then sank by 47.93% to $2.0 billion in 2023, then tumbled by 36.49% to $1.3 billion in 2024, then declined by 10.04% to $1.2 billion in 2025, then advanced by 27.9% to $1.5 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.5 billion, $1.2 billion, and $1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.